A Selection of Lipogems Canine Case Studies v1.

•

1 j'aime•330 vues

A Selection of Lipogems Canine Case Studies v1. Pg 3. Introduction to cases Pg 4. Case 1. Gilda ~ GSD, F, 8Y, UAP, DJD Pg 8. Case 2. English Setter, M, 2Y, Old elbow fracture Pg 10. Case 3. Working collie, Bicipital tendon partial tear Pg 12. Case 4. Golden Retriever, Collateral ligaments, cruciate right stifle rupture Pg 14. Case 5. Pet Dog, Arthritic post cruciate tear Pg 16. Case 6. Torn medial meniscus Pg 17. Further links and contacts

Sciences

By Lipocast Biotech UK Ltd
Lipogems Canine
Case Studies
V1.

$Pg 3. Introduction to cases Pg 4. Case 1. Gilda ~ GSD, F, 8Y, UAP, DJD Pg 8. Case 2. English Setter, M, 2Y, Old elbow fracture Pg 10. Case 3. Working collie, Bicipital tendon partial tear Pg 12. Case 4. Golden Retriever, Collateral ligaments, cruciate right stifle rupture Pg 14. Case 5. Pet Dog, Arthritic post cruciate tear Pg 16. Case 6. Torn medial meniscus Pg 17. Further links and contacts Lipogems Canine Case Studies$

Canine Sample Application Case Studies V1.
This presentation includes a range of cases from Dr Offer Zeira
and from Steve Jones and Phil Linge from Arberth Veterinary
Centre. There are hyper links to videos of the dogs on some of
the pages providing follow up viewing. To read Dr Offer Zeira’s
paper:Intra-Articular Administration of Autologous Micro-
Fragmented Adipose Tissue in Dogs with Spontaneous
Osteoarthritis: Safety, Feasibility, and Clinical Outcomes
Please click here

1. Gilda ~ GSD, F, 8Y, UAP, DJD. Click on the blue text link for the videos for.
10th May 2015 ~ 3 Days Pre-treatment 18th May 2015 ~ 5 Days Post-treatment

1. Gilda ~ GSD, F, 8Y, UAP, DJD. Click on the blue text link for the videos for.
23rd May 2015 ~ 10 Days Post-treatment 12TH January 2016 ~ 8 Months Post-treatment

1. Gilda ~ GSD, F, 8Y, UAP, DJD. Click on the blue text link for the videos for.*
4th May 2016
1 Year Post-treatment
*Note – this procedure
were performed by Dr
Offer Zeira and were
included in his IFATS
Nov 2016 Presentation

$2. English Setter, M, 2Y, Old elbow fracture *$

$4th June 2015 ~ Pre-treatment 2. English Setter, M, 2Y, Old elbow fracture. Click below the pictures to play the videos.* 16th June 2015 ~ 12 days post-treatment *Note – this procedure were performed by Dr Offer Zeira and were included in his IFATS Nov 2016 Presentation$

3. Working collie, Bicipital tendon partial tear
Date of procedure: 03/08/18
Leg Joint/articulation: left shoulder
Outcome: Walking comfortably 72 hrs post treatment. The 3 days pre-treatment
scan followed 6 weeks of “standard” conservative treatment follow treatment
with Lipogems Canine. At the 6 week scan he was reported to be “He’s walking
sound and raring to go”
Veterinary Surgery: Arberth Veterinary Centre

3. Working collie, Bicipital tendon partial tear
Post Treatment 6 week ScanPre Treatment scan

4. Golden Retriever, Collateral ligaments and cruciate right stifle rupture
Date of procedure: 10/04/17
Injury: Fell from moving vehicle
Leg Joint/articulation: Collateral
ligaments and cruciate right stifle
Activity: N/A pet dog
Outcome: Walking sound at 8 weeks post
treatment. Owner reports dog still fully
sound Aug 18
Veterinary Surgery: Arberth Veterinary
Centre

4. Golden Retriever, Collateral ligaments and cruciate right stifle rupture
Post TreatmentPre-Treatment

5. Pet Dog, Arthritic post cruciate tear
Date of procedure: 09/03/18
Injury: Arthritic post cruciate tear
Leg Joint/articulation: Left stifle
Activity: Pet dog
Outcome: Owner reports good outcome
Additional Info: sound
Veterinary Surgery: Arberth Veterinary Centre

5. Pet Dog, Arthritic post cruciate tear
Pre-Treatment
Post Treatment 6
months

Date of procedure: 12/06/18
Injury: Torn medial meniscus
Leg Joint/articulation: Left stifle
Outcome: Walking sound at 2 weeks,
continues sound and the owner is very
happy with the outcome
Veterinary Surgery: Arberth Veterinary
Centre
6. Torn medial meniscus

Further links and downloads
Follow us on social media
@Lipogemscanine
www.lipogemscanine.com
Press Portal Vet research papers/ SOP
download portal click here
To download Dr Offer Zeiras paper:
Intra-Articular Administration of Autologous
Micro-Fragmented Adipose Tissue in Dogs
with Spontaneous Osteoarthritis: Safety,
Feasibility, and Clinical Outcomes
Please click here

Contenu connexe

Similaire à A Selection of Lipogems Canine Case Studies v1.

Xenotransplantation

Anwesha Banerjee

Client oriented approach for physical examination of animals

Himanshu Pandey

Infliximab

Amanda Gray

Effect of ethanol_stem_extract_of_homalium_letestui_on_histological_features_...

oyepata

9 bizarre scientific discoveries

Mpower Medical Inc

Surgical terms and reasons for surgery

Dr.Jigdrel Dorji

Lipocast Biotech UK Lipogems Equine Veterinary Presentation 2017 v.1.4 - With...

Lipogems Equine & Lipogems Canine

What is Wrong with Animal Experiments

v2zq

Lipocast Biotech UK Lipogems Equine Veterinary Presentation 2017 v.1.4 - With...

Lipogems Equine & Lipogems Canine

Regardless of the mobile applications available in smartphones, the veterinary hospitals in Sri Lanka still use manual books to fill the vaccination schedule and keep track of pet care. This research is an attempt to change this tradition by introducing a smart system for dogs. The system can be used both by dog lovers and veterinary doctors. In this study, new proposed application plan is to replace the traditional method with a method that can store the information into a system and make it available for the users to take care of the dog. Since the dog's birth, the information can be stored and it will assist the pet owners. Unlike other applications available, the advantage of this application is that the user can choose applications to be used individually or integrated according to their choice.

Smart dog caring system

Lakshanya Krishnarajan

ORGAN PRESERVATION AT MGCHRI

Kanhu Charan

Piglet Processing.pptx

DyesebelAndaya

Effects of Losartan on Ischemia/Reperfusion–Induced Testicular Injury in a Ra...

ANALYTICAL AND QUANTITATIVE CYTOPATHOLOGY AND HISTOPATHOLOGY

April W. Armstrong, MD, MPH, prepared useful practice aids pertaining to psoriasis management for this CME activity titled "Stories From the Psoriasis CaseBook: Overcoming Challenges in Diagnosis and Treatment for Family Physicians." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2n9Pfxg. CME credit will be available until August 9, 2019.

Stories From the Psoriasis CaseBook: Overcoming Challenges in Diagnosis and T...

PVI, PeerView Institute for Medical Education

First aid.ppt

Dr.hema hassan

（EOR/MEOR/BERO/oil recovery）After feed with enzyme solution, mice slightly quiet for a few moments and resume to normal activities, animals without acute death. We continue to observe mice but still no mice dead after seven days. No abnormal secretions from mice’s natural holes and activity, diet, color were normal, also no abnormal changes for mice’s feces and urine within 7days; the weight is 27.55±3.6g, net weight is 7.95g within seven days. Put the mice to death after 7days; observe the heart, liver, lung, spleen, kidney, gastrointestinal and other organs showed no abnormality. The maximum dose of the test gavage is 10.20g/kg still cannot cause the mice to death. This explains the maximum tolerated dose (LD0) is greater than 10g/kg. According to the acute toxicity test of acute toxicity classification GB15193.3-94, this enzyme should be nontoxic.

（EOR/MEOR/BERO/oil recovery）Animal acute toxicity test

Matt Wu

IFATS Presentation by Dr offer Zeira - 2016 20.11.16

Lipogems Equine & Lipogems Canine

Vet Times 2017 Lipogems Canine Feature - Novel regeneration therapy available...

Lipogems Equine & Lipogems Canine

To spay and neuter or not to spay and neuter

Random Sandi

Similaire à A Selection of Lipogems Canine Case Studies v1. (19)

Xenotransplantation

Client oriented approach for physical examination of animals

Infliximab

Effect of ethanol_stem_extract_of_homalium_letestui_on_histological_features_...

9 bizarre scientific discoveries

Surgical terms and reasons for surgery

Lipocast Biotech UK Lipogems Equine Veterinary Presentation 2017 v.1.4 - With...

What is Wrong with Animal Experiments

Lipocast Biotech UK Lipogems Equine Veterinary Presentation 2017 v.1.4 - With...

Smart dog caring system

ORGAN PRESERVATION AT MGCHRI

Piglet Processing.pptx

Effects of Losartan on Ischemia/Reperfusion–Induced Testicular Injury in a Ra...

Stories From the Psoriasis CaseBook: Overcoming Challenges in Diagnosis and T...

First aid.ppt

（EOR/MEOR/BERO/oil recovery）Animal acute toxicity test

IFATS Presentation by Dr offer Zeira - 2016 20.11.16

Vet Times 2017 Lipogems Canine Feature - Novel regeneration therapy available...

To spay and neuter or not to spay and neuter

Plus de Lipogems Equine & Lipogems Canine

Equestrian Life June 2019

Lipogems Equine & Lipogems Canine

Intra-Articular Administration of Autologous Micro-Fragmented Adipose Tissue in Dogs with Spontaneous Osteoarthritis: Safety, Feasibility, and Clinical Outcomes OFFER ZEIRA,a SIMONE SCACCIA,a LETIZIA PETTINARI,a ERICA GHEZZI,a NIMROD ASIAG,a LAURA MARTINELLI,a DANIELE ZAHIRPOUR,a MARIA P. DUMAS,a MARTIN KONAR,a DAVIDE M. LUPI,a LAURENCE FIETTE,b LUISA PASCUCCI,c LEONARDO LEONARDI,c ALISTAIR CLIFF,d GIULIO ALESSANDRI,e AUGUSTO PESSINA,f DANIELE SPAZIANTE,g MARINA ARALLAa ABSTRACT Similar to the disease affecting humans, osteoarthritis (OA) is a painful musculoskeletal condition affecting 20% of the adult canine population. Several solutions have been proposed, but the results achieved to date are far from being satisfactory. New approaches, such as intra-articular delivery of cells (including mesenchymal stromal cells), have been proposed. Among the many sources, the adipose tissue is considered very promising. We evaluated the safety, feasibility, and efficacy of a single intra-articular injection of autologous and micro-fragmented adipose tissue (MFAT) in 130 dogs with spontaneous OA. MFAT was obtained using a minimally invasive technique in a closed system and injected in the intra- and/or peri-articular space. Clinical outcomes were determined using orthopedic examination and owners’ scores for up to 6 months. In 78% of the dogs, improvement in the orthopedic score was registered 1 month after treatment and continued gradually up to 6 months when 88% of the dogs improved, 11% did not change, and 1% worsened compared with baseline. Considering the owners’ scores at 6 months, 92% of the dogs significantly improved, 6% improved only slightly, and 2% worsened compared with baseline. No local or systemic major adverse effects were recorded. The results of this study suggest that MFAT injection in dogs with OA is safe, feasible, and beneficial. The procedure is time sparing and cost-effective. Post injection cytological investigation, together with the clinical evidence, suggests a long-term pain control role of this treatment. The spontaneous OA dog model has a key role in developing successful treatments for translational medicine. STEM CELLS TRANSLATIONAL MEDICINE 2018;00:1–10

Intra-Articular Administration of Autologous Micro-Fragmented Adipose Tissue ...

Lipogems Equine & Lipogems Canine

Lipocast bitoech uk privacy and data protection policy

Lipogems Equine & Lipogems Canine

Lipogems regenerative medicine seminar by lipocast biotech uk itinerary for s...

Lipogems Equine & Lipogems Canine

THE company behind an innovative product “that is revolutionising how vets are able to treat tendon and ligament injuries” is planning a seminar in May to showcase treatment options, techniques, the science and clinical data. Lipocast Biotech UK brought Lipogems Equine and Canine to the UK market and said the treatment had “grown exponentially” in 2017 due to success accredited veterinary surgeons are seeing in equine and canine patients. Use in international veterinary schools is adding to positive testaments of the treatment’s capability, the firm said. A database of studies is being compiled for both equine and canine patients, with Tim Watson, of Waterlane Equine Vets, Gloucestershire, leading collection of the equine data. Lipogems offers, says Lipocast, a rapid and cost-effective means of harvesting mesenchymal stromal cells (MSCs), helping vets treat tendon and ligament injuries and manage degenerative joint diseases. Lipogems harnesses, says Lipocast Biotech, the potential of pericyte cells that surround capillaries. Following tissue injury, pericytes detach from the capillaries and gradually convert into activated MSCs and begin the process of orchestrating tissue repair. The Lipogems technique delivers MSCs from pericytes in adipose tissue that are collected by liposuction, flushed and processed using gentle mechanical disruption. These MSCs understand the nature of the injury into which they are injected and then stimulate and coordinate numerous biological processes for effective healing. For equine veterinary surgeons, the procedure can be performed stable-side in 40 minutes, with no additional culture or laboratory time is required. Lipocast Biotech UK has now announced the inaugural Lipogems Regenerative Medicine Seminar will be held on 16 May in Cirencester, Gloucestershire. The seminar, which offers five CPD hours, is free of charge, and leading vets will give lectures about the future of regenerative medicine and the science behind the technology, with case-based evidence and procedure demonstrations presented. Dr Watson said: “Lipogems is an easy technique that can be performed at the patient's side and enables prompt treatment for a wide range of common orthopaedic conditions affecting horses and ponies. The results are superior to other regenerative therapies currently used.” For more details about the seminar, email lucy_wilson@lipogemsequine.com

Vet Times February Issue 2018

Lipogems Equine & Lipogems Canine

Lipocast Biotech UK Lipogems Equine and Canine Presentation 2017 v.1.2 - With...

Lipogems Equine & Lipogems Canine

Lipocast Biotech UK Lipogems Canine Standard Operating Procedure v1

Lipogems Equine & Lipogems Canine

Lipocast Biotech UK Lipogems Equine Standard Operating Procedure 007 - withou...

Lipogems Equine & Lipogems Canine

The Effect of Intra-articular Injection of Autologous Microfragmented Fat Tissue on Proteogly can Synthesis in Patients with Knee Osteoarthritis Damir Hudetz 1,2,3,*, Igor Borić 1,4,5, Eduard Rod 1, Željko Jeleč 1, Andrej Radić 1, Trpimir Vrdoljak 1,2, Andrea Skelin 1,6, Gordan Lauc 6,7, A prospective, non-randomized, interventional, single-center, open-label clinical trial was conducted from January 2016 to April 2017 Results The results of our study indicate that the use of autologous and micro-fragmented adipose tissue in patients with knee OA (measured by dGEMRIC MRI) increased glycosaminoglycan (GAG) content in hyaline cartilage, which is in line with observed VAS and clinical results.

The Effect of Intra-articular Injection of Autologous Microfragmented Fat Tis...

Lipogems Equine & Lipogems Canine

Minimal Criteria for Defining MSC's. The ISCT Position Statement

Lipogems Equine & Lipogems Canine

Mammalian MSC from Selected Species: Features and Applications Christiane Uder, Sandra Br€uckner, Sandra Winkler, Hans-Michael Tautenhahn,†‡ Bruno Christ†* Mesenchymal stromal/stem cells (MSC) are promising candidates for cellular therapy of different diseases in humans and in animals. Following the guidelines of the International Society for Cell Therapy, human MSC may be identified by expression of a specific panel of cell surface markers (CD1051, CD731, CD901, CD34-, CD14-, or CD11b-, CD79- or CD19-, HLA-DR-). In addition, multiple differentiation potential into at least the osteogenic, adipogenic, and chondrogenic lineage is a main criterion for MSC definition. Human MSC and MSC of a variety of mammals isolated from different tissues meet these criteria. In addition to the abovementioned, they express many more cell surface markers. Yet, these are not uniquely expressed by MSC. The gross phenotypic appearance like marker expression and differentiation potential is similar albeit not identical for MSC from different tissues and species. Similarly, MSC may feature different biological characteristics depending on the tissue source and the isolation and culture procedures. Their versatile biological qualities comprising immunomodulatory, anti-inflammatory, and proregenerative capacities rely largely on the migratory and secretory capabilities of MSC. They are attracted to sites of tissue lesion and secrete factors to promote self-repair of the injured tissue. This is a big perspective for clinical MSC applications in both veterinary and human medicine. Phase I/II clinical trials have been initiated to assess safety and feasibility of MSC therapies in acute and chronic disease settings. Yet, since the mode of MSC action in a specific disease environment is still unknown at large, it is mandatory to unravel the response of MSC from a given source onto a specific disease environment in suitable animal models prior to clinical applications.

Mammalian MSC from Selected Species: Features and Applications Christiane Ude...

Lipogems Equine & Lipogems Canine

Adipose Tissue and Mesenchymal Stem Cells: State of the Art and Lipogems® Technology Development Carlo Tremolada1 & Valeria Colombo1 & Carlo Ventura2 Abstract Inthepastfewyears,interestinadiposetissueasan ideal source of mesenchymal stem cells (MSCs) has increased. These cells are multipotent and may differentiate in vitro into several cellular lineages, such as adipocytes, chondrocytes, osteoblasts, and myoblasts. In addition, they secrete many bioactive molecules and thus are considered Bmini-drugstores.^ MSCs are being used increasingly for many clinical applications, such as orthopedic, plastic, and reconstructive surgery. Adipose-derived MSCs are routinely obtained enzymatically from fat lipoaspirate as SVF and/or may undergo prolonged ex vivo expansion, with significant senescence and a decrease in multipotency, leading to unsatisfactory clinicalresults.Moreover, these techniquesare hampered by complex regulatory issues. Therefore, an innovative technique (Lipogems®; Lipogems International SpA, Milan, Italy) was developed to obtain microfragmented adipose tissue with an intact stromal vascular niche and MSCs with a high regenerative capacity. The Lipogems® technology, patented in 2010 and clinically available since 2013, is an easyto-use system designed to harvest, process, and inject refined fat tissue and is characterized by optimal handling ability and a great regenerative potential based on adipose-derived MSCs. In this novel technology, the adipose tissue is washed, emulsified, and rinsed and adipose cluster dimensions gradually are reduced to about 0.3 to 0.8 mm. In the resulting Lipogems® product, pericytes are retained within an intact stromal vascular niche and are ready to interact with the recipient tissue after transplantation, thereby becoming MSCs and starting the regenerative process. Lipogems® has been used in more than 7000 patients worldwide in aesthetic medicineandsurgery,aswellasinorthopedicandgeneralsurgery, with remarkable and promising results and seemingly no drawbacks. Now, several clinical trials are under way to supporttheinitialencouragingoutcomes.Lipogems®technology is emerging as a valid intraoperative system to obtain an optimal final product that may be used immediately for regenerative purposes.

Adipose Tissue and Mesenchymal Stem Cells: State of the Art and Lipogems® Tec...

Lipogems Equine & Lipogems Canine

Angiogenic and anti-inflammatory properties of micro-fragmented fat tissue and its derived mesenchymal stromal cells Valentina Ceserani1†, Anna Ferri1*†, Angiola Berenzi2, Anna Benetti2, Emilio Ciusani3, Luisa Pascucci4, Cinzia Bazzucchi4, Valentina Coccè5, Arianna Bonomi5, Augusto Pessina5, Erica Ghezzi6, Offer Zeira6, Piero Ceccarelli4, Silvia Versari7, Carlo Tremolada7 and Giulio Alessandri1 Background: Adipose-derived mesenchymal stromal cells (Ad-MSCs) are a promising tool for advanced cell-based therapies. They are routinely obtained enzymatically from fat lipoaspirate (LP) as SVF, and may undergo prolonged ex vivo expansion, with significant senescence and decline in multipotency. Besides, these techniques have complex regulatory issues, thus incurring in the compelling requirements of GMP guidelines. Hence, availability of a minimally manipulated, autologous adipose tissue would have remarkable biomedical and clinical relevance. For this reason, a new device, named Lipogems® (LG), has been developed. This ready-to-use adipose tissue cell derivate has been shown to have in vivo efficacy upon transplantation for ischemic and inflammatory diseases. To broaden our knowledge, we here investigated the angiogenic and anti-inflammatory properties of LG and its derived MSC (LG-MSCs) population.

Angiogenic and anti-inflammatory properties of micro-fragmented fat tissue an...

Lipogems Equine & Lipogems Canine

Lipocast Biotech UK Lipogems Equine and Canine Presentation 2017 v.1.2

Lipogems Equine & Lipogems Canine

Veterinary Record - Lipogems story - Regenerative therapy for canine joint co...

Lipogems Equine & Lipogems Canine

Vet Practice News January 2017 - News Story

Lipogems Equine & Lipogems Canine

Polo Times August 2017 - Saving Champions Feature

Lipogems Equine & Lipogems Canine

Plus de Lipogems Equine & Lipogems Canine (17)